Share Twitter LinkedIn Facebook Email Douglas W. Blayney, MD, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer.
ASCO 2025 Guidelines on Sentinel Lymph Node Biopsy for Early-Stage Breast Cancer: A Game-Changer in Oncology ASCO 5 Mins Read
2025 Breast Cancer Updates: Dr. Evanthia Roussos Torres on Biomarkers, Immunotherapy, and the Future of Treatment – MOASC Breast 6 Mins Read